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New molecular and therapeutic insights into canine
diffuse large B-cell lymphoma elucidates the role of
the dog as a model for human disease
Diffuse large B-cell lymphoma (DLBCL) is the com-
monest lymphoma in both humans and dogs.1 Due to
spontaneously high incidence, complex genetic interplay,
aggressive clinical course, elevated frequency and the
presence of an intact immune system, dogs with lym-
phoma are considered as an ideal comparative model for
drug development for human lymphomas.1 The BCL2
inhibitor venetoclax and the BTK inhibitors ibrutinib and
acalabrutinib are examples of drugs that benefited from
such a model.2-4 Clinical heterogeneity of canine DLBCL
(cDLBCL) is known and early insights into its biological
and molecular mechanisms, revealing similarities with
the human counterpart, have been reported, but a
genomic characterization of this tumor has never been
provided. Furthermore, a complete understanding of the
molecular mechanisms driving the pathogenesis of
cDLBCL is necessary to take more accurate advantage of
this comparative model and, also, to improve the clinical
outcome of the dogs. In this study, we report the first
large integrated analysis with transcriptome sequencing,
methylation genome-wide analysis, copy number varia-
tion analysis and clinical outcome in cDLBCL to identify
the molecular mechanisms of this tumor comprehensive-
ly and to define its use in comparative medicine better.
We first compared the transcriptome obtained via
RNA-sequencing in 50 cDLBCL versus that from RNA-
sequencing data of normal follicular B cells derived from
lymph nodes of 11 healthy dogs (Online Supplementary
Table S1; Online Supplementary Methods). Transcripts with
levels higher in cDLBCL than in controls were significant-
ly enriched in genes coding for proteins involved in the B-
cell receptor (BCR), MYC signaling, PI3K/AKT/mTOR
pathway, DNA replication, and cell cycle (Online
Supplementary Figure S1). Genes coding for proteins
involved in the nuclear factor-kB (NF-kB) pathway
(CD79, CD19, SYK, LYN, CARD11, BCL10, BTK,
TRAF6, MYD88, NFKB2, TLR7, TLR9) were also differ-
entially expressed (Figure 1). The aberrant expression of
these genes might contribute to enhance the proliferation
of B cells and protect these cells from apoptosis by stim-
ulating NF-κB activity. A similar mechanism has been
described in human activated B-cell DLBCL, character-
ized by constitutive activation of NF-kB due to mutations
in multiple genes belonging to this subgroup’s pathway.5
These data fit with the reported frequent inactivation of
the NF-kB negative regulator TRAF3 in canine B-cell lym-
phomas6 and the anti-tumor activity of BTK inhibitors,
specifically active in the human activated B-cell subtype
of DLBCL and experimentally used in canine B-cell lym-
phomas.3,4 
The protein-encoding gene LIN28B appeared as the
most upregulated transcript in tumors. While LIN28B
does not seem to be a relevant gene for human DLBCL,
it is involved in the activation of the NF-kB pathway and
MYC in different human and mouse tumor models and
its overexpression causes murine peripheral T-cell lym-
phomas.7 We took advantage of the CLBL-1 cell line, the
only in vitro model available of cDLBCL, which showed a
profile similar to cDLBCL clinical specimens, with
LIN28B as the most overexpressed gene compared to
expression levels in normal lymph nodes (Online
Supplementary Table S3). LIN28B silencing using locked
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Figure 1. Schematic representation of a potential nuclear factor-kB activation pathway obtained by RNA-sequencing analysis in canine diffuse large B-cell
lymphomas. Red, upregulated genes. Green, downregulated genes. Yellow, genes that are neither upregulated or downregulated. 
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Figure 2. Unsupervised clustering of canine
diffuse large B-cell lymphoma RNA-
sequencing data and prognostic impact of
PD-L1 and PD-1 expression. (A)
Multidimensional scaling plot of all the sam-
ples demonstrated a clear separation
between normal B cells (green dots) and
canine diffuse large B-cell lymphomas
(cDLBCL) (red dots). (B) Two cDLBCL sub-
groups (blue and red) were defined by hier-
archical clustering. (C,D) Kaplan-Meier plots
of overall survival (C) and event-free survival
(D) of cDLBCL grouped on the basis of their
RNA-sequencing profiles. (E-H) Prognostic
impact of PD-L1 tumor expression and PD-1
residual lymphocyte expression on overall
survival and event-free survival in cDLBCL:
Kaplan-Meier plots of overall survival (E,G)
and event-free survival (F,H) based on












nucleic acid-modified short interfering RNA led to a
reduction in cell proliferation compared to that of the
negative control (Online Supplementary Figure S2), open-
ing new therapeutic perspectives, at least in cDLBCL. 
The integration of data on copy number variations and
the transcriptome showed an association in 320 genes. A
total of 239 genes were located in regions of gains and
simultaneously overexpressed, while 81 genes were
downregulated and mapped to regions of deletions
(Online Supplementary Table S4). Gains of the entire chro-
mosomes 13 and 31 and loss of chromosome 14 were the
most frequent aberrations, occurring in >20% of the
cases (Online Supplementary Figure S3). Survival analysis
showed a trend to longer overall survival and event-free
survival in dogs affected by this chromosome 13 aberra-
tion than in the remaining animals (P=0.134). A series of
additional copy number variations, such as gains in chro-
mosomes 4 and 27 and loss in chromosome 28, were
observed in at least two dogs (Online Supplementary Figure
S2).
A genome-wide next-generation sequencing-based
methylation analysis, previously never performed in
canine lymphomas, identified differentially methylated
regions between cDLBCL and normal follicular B cells
(Online Supplementary Table S4; Online Supplementary
Figures S4 and S5). In accordance with RNA-sequencing
data, genes that had a reduced degree of promoter
methylation in cDLBCL were enriched for transcripts
involved in cytokine/cytokine receptor interactions, BCR
and JAK/STAT signaling. Genes participating in calcium
signaling, cytoskeleton, Hedgehog/Wnt signaling and
metabolism more commonly showed increased promoter
methylation in neoplastic cells than in normal B cells and
were also down-regulated (Online Supplementary Table
S4). In line with the findings of our previous study,8 this
observed increased promoter methylation supports an
evaluation of the use of hypomethylating agents in the
treatment of cDLBCL. 
Unsupervised clustering of RNA-sequencing data sepa-
rated cDLBCL from normal follicular B cells (Figure 2A)
and identified two distinct subgroups within the tumors
(Figure 2B). The two groups did not overlap with either
the human germinal center B-cell or activated B-cell sub-
types of DLBCL or the DLBCL consensus clusters,5 but
they were associated with different overall survival (278
vs. 150 days, P<0.01) and event-free survival (179 vs. 113
days, P=ns) (Figure 2C,D). Tumors belonging to the
group with worse prognosis were characterized by a
higher expression of transcripts for proteins involved in
apoptosis, JAK/STAT signaling, microenvironment,
inflammatory response and the P53 pathway (Online
Supplementary Table S5). In particular, dogs with the poor-
est outcome had a signature largely defined by markers of
T-cell-mediated immune responses, with higher expres-
sion of transcripts involved in T-cell and macrophage reg-
ulation (CD163, CD96, PD-1, PDL-1, CTLA4, CD8a,
CD4), as also shown by an enrichment of gene expres-
sion signatures of immune-inhibitory molecules (Online
Supplementary Figure S6), and genes associated with the
ATP-binding cassette transporter. The clustering into two
distinct DLBCL subgroups was also supported by methy-
lation data and differences in copy number variations
(Online Supplementary Figure S7). Cases with inferior out-
come had a higher degree of promoter methylation
(P<0.005), and a higher number of aberrations (P<0.01)
compared to the remaining cases, but no equivalent to
the human 9p24 amplification associated with expres-
sion of PD-L1, which could be mainly supported by the
observed activation of the JAK/STAT pathway. 
We first validated the pattern of expression of PDL-1,
PD-1, CTLA-4 and CD5 by immunohistochemistry
(Online Supplementary Figure S8). All 25 samples from the
group with a poor outcome were strongly positive for
PDL-1 and CTLA-4 (tumor proportion score: >50%),
while cases in the other cluster were completely negative
(n=5, 20%) or weakly positive (tumor proportion score:
1%-40%; n=20, 80%). The same cases also presented a
higher number of PD-1+ and CD5+ cells (higher or lower
than 20 per high power field). We then analyzed an inde-
pendent series of 44 cDLBCL, all treated with CHOP
(cyclophosphamide, doxorubicin, vincristine and pred-
nisone) plus vaccine.9 Staining for PDL-1 and PD-1 was
positive in 21 (48%) and 25 cases (57%), respectively,
and conferred inferior outcome (Figure 2E,F). CTLA-4
and CD5 were expressed in 18 (41%) and 22 cases
(50%), respectively, but were not associated with clinical
outcome. In a multivariate analysis including bone mar-
row infiltration and substage, PD-L1 and PD-1 main-
tained their prognostic impact on overall survival, but not
on event-free survival (Online Supplementary Table S6).
The results obtained represent a solid foundation on
which to evaluate novel regimens based on immune-
checkpoint inhibitors in canine lymphomas before mov-
ing to the human setting. A combination of immune-
checkpoint modulators with active vaccines9 would also
be worth exploring.
The transcriptome data had potential therapeutic
implications. First, cDLBCL showed gene expression sig-
natures suggestive of MYC activation and we therefore
assessed the BET inhibitor birabresib (MK-
8628/OTX015)10 and the BRD4 degrader MZ1 (along-
side its inactive epimer cis MZ1)11 for their ability to block
the proliferation of CLBL-1 cells.12 Both drugs inhibited
proliferation, although MZ1 was more potent (Online
Supplementary Figure S9A), in accordance with data
obtained in human DLBCL models.13 Interestingly, MZ1
significantly downregulated not only MYC, but also
LIN28B (Online Supplementary Figure S9B). Second, also in
agreement with a transcriptome study based on a small
number of canine B-cell lymphomas,14 genes belonging to
the PI3K/AKT/mTOR pathway and/or to gene expres-
sion signatures obtained in human DLBCL cell lines
exposed to BCR inhibitors15 were enriched for transcripts
expressed in cDLBCL and in the CLBL-1 cell line (Online
Supplementary Figure S10). We therefore tested a dual
PI3K/mTOR inhibitor bimiralisib (PQR309) and PI3Kδ
inhibitor idelalisib. Both drugs were active in the CLBL-1
cell line with half maximal inhibitory concentration (IC50)
values of 150 nM and 80 nM, respectively (Online
Supplementary Figure S9C). A xenograft model with
CLBL-1 implanted in NOD-SCID mice showed that both
bimiralisib and MZ1, given at the dose of 100 mg/kg, sig-
nificantly affected tumor growth in comparison with that
in the control group, with reductions in the tumor vol-
ume on day 8 of 43% and 33%, respectively, compared
to the control tumor volume (P<0.05) (Online
Supplementary Figure S9D).  
In conclusion, we identified deregulated pathways and
individual transcripts providing therapeutic targets,
including an immune-related signature affecting the out-
come of a subgroup of cDLBCL. Our study provides a
series of novel findings that allow a better understanding
of cDLBCL as a comparative model for human DLBCL
but will also lead to improvements in the management of
dogs in veterinary clinical practice.  
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